[OncotypeDX in breast cancer]
Luxardo R, Garcia Marti S, Lazo E, Alfie V, Ciapponi A, Augustovski F, Bardach A, Alcaraz A, Pichon Riviere A
Record ID 32018004427
Spanish
Original Title:
OncotypeDX en cáncer de mama
Authors' recommendations:
Moderate-quality evidence shows that OncotypeDX® probably provides a significant net benefit in patients with HR+/HER2- early breast cancer and with intermediate risk of distant recurrence, given its performance in predicting chemotherapy benefits.
The clinical practice guidelines consulted suggest using OncotypeDX® as one of the genetic test options in patients where indication for adjuvant chemotherapy is uncertain. United States, France, Germany and United Kingdom health funders cover OncotypeDX®. The Latin American and Argentinian health funders do not mention this technology. The United Kingdom considers this technology to be cost-effective, as any of the other genetic tests available.
No local economic evaluations on the cost-effectiveness of OncotypeDX® have been found.
Details
Project Status:
Completed
Year Published:
2022
URL for published report:
https://www.iecs.org.ar/publicacion/?id=22519
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Breast Neoplasms
- Genetic Testing
- Chemotherapy, Adjuvant
- Biomarkers, Tumor
- Neoplasm Recurrence, Local
- Prognosis
- Gene Expression Profiling
- Receptors, Estrogen
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.